Study on Bortezomib for Treating Advanced Prostate Cancer with PTEN Deletion

Inclusion Criteria

• Men aged 18 years or older.
• Diagnosed with prostate cancer confirmed by lab tests, without small cell features.
• Have had surgery to remove the testicles or are on ongoing hormone therapy, with low testosterone levels.
• Previously treated with at least one advanced hormone therapy, such as abiraterone or enzalutamide.
• No prior systemic treatment for mCRPC, except for certain hormone therapies.
• Available tumor tissue sample or able to provide a new biopsy.
• Have a PTEN gene deletion confirmed by genetic testing.
• Cancer must be progressing according to the study doctor.
• General health status score of 0 to 2, indicating full activity or some restriction in strenuous activities.
• Adequate organ function based on specific blood tests.
• Agree to use effective contraception during the study and for 4 months after the last dose.
• Recovery from any previous treatment side effects to a mild level.
• Able to understand and sign a consent form.
• Life expectancy of more than 3 months.

Exclusion Criteria

• Have nerve damage of grade 2 or higher.
• Currently receiving other experimental treatments.
• Have had other cancer treatments or experimental drugs within 14 days before starting the study.
• Have had major surgery within 14 days before starting the study and not fully recovered.
• Diagnosed with another cancer within the last 2 years, except for certain skin or localized cancers.
• Have known brain metastases or disease affecting the brain lining, unless treated and stable for at least 4 weeks.
• Have uncontrolled or significant health issues, such as severe heart problems or recent stroke.
• Have a known HIV infection with a detectable viral load, unless on effective treatment.
• Have active infections like tuberculosis or hepatitis B or C, unless resolved or controlled.
• Have severe allergies to the study drug or its components.
• Taking medications that are not allowed during the study, unless stopped for a sufficient time before starting treatment.